Pancreatic cancer

Can-Fite Reports 2023 Financial Results and Clinical Update

Retrieved on: 
Thursday, March 28, 2024
Oncology, Health, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, Human, Psoriasis, Exercise, ALT, Patent, BID, CANF, Patient, CEE, Journal, Policy, EMA, Security (finance), Inflammation, Cancer, Bank statement, European Medicines Agency, Pancreatic cancer, Annual report, Skin, The Annual Report, PASI, Safety, NASH, Use, Liver cancer, FDA, Food, DSM-IV codes, Pharmaceutical industry

(NYSE American: CANF) (TASE: CANF), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address oncological and inflammatory diseases, today announced financial results and clinical updates for the twelve months ended December 31, 2023.

Key Points: 
  • (NYSE American: CANF) (TASE: CANF), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address oncological and inflammatory diseases, today announced financial results and clinical updates for the twelve months ended December 31, 2023.
  • EADV is a top ranked peer reviewed journal (impact factor 9.2) that publishes articles on clinical and basic science topics in dermatology.
  • Financial income (expense), net for the year ended December 31, 2023 aggregated $0.56 million compared to financial expense, net of $(0.07) for the year ended December 31, 2022.
  • The Company's consolidated financial results for the year ended December 31, 2023 are presented in accordance with US GAAP Reporting Standards.

Bristol Myers Squibb Expands Health Equity Grant Initiatives to Improve Health Outcomes

Retrieved on: 
Tuesday, March 26, 2024
Other Philanthropy, Biotechnology, Pharmaceutical, Managed Care, Oncology, Health, Philanthropy, Clinical Trials, Well, Diagnosis, BMY, World Health Organization, Patients Association, Less, Organization, Social, Education, Bone marrow, Survival, Health equity, Social support, Genetics, Patient, Good Health, Corporate Affairs, Pancreatic cancer, Cancer, Anti-transglutaminase antibodies, Bristol Myers Squibb, Blood Cancer UK, United, Telephone numbers in Hungary, Sistema, Oral cancer, Clinical trial, WHO, Multimedia, Hepatocellular carcinoma, Nursing

Bristol Myers Squibb (NYSE: BMY) today unveiled a $1.8 million initiative to advance health equity by addressing social determinants of health (SDoH) in four countries with underserved patient needs, including Brazil, India, Thailand, and the United Kingdom.

Key Points: 
  • Bristol Myers Squibb (NYSE: BMY) today unveiled a $1.8 million initiative to advance health equity by addressing social determinants of health (SDoH) in four countries with underserved patient needs, including Brazil, India, Thailand, and the United Kingdom.
  • The new health equity grants are an extension of the company’s broader long-term commitment to invest $150M in health equity by 2025 .
  • At Bristol Myers Squibb, health equity is the opportunity for all people and communities across the globe to attain their full potential for health and well-being.
  • Our work extends beyond traditional healthcare boundaries, emphasizing the importance of community voices and cross-sector partnerships in co-creating solutions that drive meaningful and equitable health outcomes worldwide.

TriSalus Life Sciences Announces Oral Presentations at the Upcoming 2024 Society of Interventional Radiology (SIR) Annual Scientific Meeting

Retrieved on: 
Thursday, March 21, 2024
Biotechnology, Other Health, Health, Radiology, Pharmaceutical, Oncology, Other Science, Medical Devices, Research, Science, Clinical Trials, Interventional radiology, Pressure, Immunotherapy, Drug, Safety, Partnership, Patient, Pancreas, Tumor microenvironment, Society of Interventional Radiology, Metastasis, Publication, Pancreatic cancer, Therapy, FACS, FDA, Liver, SIR, Food, Medical imaging

The TriSalus approach seeks to address many of the key challenges associated with delivering therapeutics to pancreas tumors.

Key Points: 
  • The TriSalus approach seeks to address many of the key challenges associated with delivering therapeutics to pancreas tumors.
  • In contrast to the liver, pancreas arteries feeding tumors are difficult to access and venous access affords anatomic advantages.
  • Presentation details for SIR 2024 are as follows:
    Presentation: Clinical Efficacy of Pressure-Enabled Transarterial Embolization of Hypovascular, Treatment-Refractory Metastases.
  • Location: Salt Lake Palace Convention Center, Room 255B
    The presentations will be available on the publications page of the TriSalus website following the respective sessions.

Lantern Pharma Reports Fourth Quarter & Fiscal Year 2023 Financial Results and Business Highlights

Retrieved on: 
Monday, March 18, 2024
Research, Technology, Clinical Trials, Biotechnology, Pharmaceutical, Health, Science, Oncology, Artificial Intelligence, Other Science, Lymphoma, Patient, GBM, Artificial intelligence, Brain, Metadata, Pancreatic cancer, Lung cancer, Mantle cell lymphoma, Clinical trial, Therapy, Harmonic, ATM, USD, PD-1, MCL, DHL, Central nervous system, CNS, DNA, Starlight, Fox Chase Cancer Center, Glioblastoma, Cancer, Safety, Liquid biopsy, Calendar, ADC, TP53, NSCLC, ATRT, AI, AACR, Drug development, Machine learning, FDA, Annual general meeting, Incidence, Triple-negative breast cancer, NHL, Patent, Pharmaceutical industry

“This past quarter and the entire year of 2023 was a period of meaningful and remarkable progress for our programs and our AI platform at Lantern Pharma.

Key Points: 
  • “This past quarter and the entire year of 2023 was a period of meaningful and remarkable progress for our programs and our AI platform at Lantern Pharma.
  • During the 4th quarter of 2023, Lantern filed 3 new patent applications culminating in 11 new patent applications for the calendar year 2023.
  • The cash burn rate for the 4th quarter and full year of 2023 continues to reflect our capital-efficient, collaborator-centered business model.
  • Full Year Net Loss: Net loss per share was $1.47 per share for the fiscal year 2023 compared to $1.31 per share for the fiscal year 2022.

Verastem Oncology Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Business Updates

Retrieved on: 
Thursday, March 14, 2024
Biotechnology, Health, Pharmaceutical, Clinical Trials, Oncology, Strategic management, Diagnosis, Initiation, Research and development, Conference, Immunotherapy, Part, FAK, New Drug Application, Patient, Cancer, RAMP, Accelerated approval (FDA), NDA, Table, SGO, BRAF, Society, IND, Abstract, Bank statement, AACR, Pancreatic cancer, Investment, Verastem Oncology, MEK, Therapy, Safety, GAAP, Gynecologic Oncology (journal), Food, FDA, Annual general meeting, Pharmaceutical industry

Verastem Oncology ended the fourth quarter of 2023 with cash, cash equivalents and investments of $137.1 million.

Key Points: 
  • Verastem Oncology ended the fourth quarter of 2023 with cash, cash equivalents and investments of $137.1 million.
  • Research & development expenses for the 2023 Quarter were $22.5 million, compared to $10.7 million for the 2022 Quarter.
  • Selling, general & administrative expenses for the 2023 Quarter were $8.6 million, compared to $6.1 million for the 2022 Quarter.
  • These non-GAAP financial measures exclude certain amounts or expenses from the corresponding financial measures determined in accordance with GAAP.

RenovoRx to Present at the 36th Annual ROTH Conference on March 19, 2024

Retrieved on: 
Tuesday, March 12, 2024
Oncology, Health, Other Health, General Health, Clinical Trials, Pharmaceutical, Biotechnology, Conference, Death, Pancreatic cancer, Pharmaceutical industry

(“RenovoRx” or the “Company”) (Nasdaq: RNXT), a clinical-stage biopharmaceutical company developing novel precision oncology therapies based on a local drug-delivery platform, today announced that Shaun Bagai, RenovoRx’s Chief Executive Officer, will present at the 36th Annual ROTH Conference to be held March 17-19, 2024 in Dana Point, CA.

Key Points: 
  • (“RenovoRx” or the “Company”) (Nasdaq: RNXT), a clinical-stage biopharmaceutical company developing novel precision oncology therapies based on a local drug-delivery platform, today announced that Shaun Bagai, RenovoRx’s Chief Executive Officer, will present at the 36th Annual ROTH Conference to be held March 17-19, 2024 in Dana Point, CA.
  • Mr. Bagai will meet with investors and participate in a fireside chat hosted by Jonathan Aschoff, Senior Research Analyst at Roth MKM on Tuesday, March 19, 2024 at 10:00 am PT.
  • Mr. Bagai will discuss recent Company milestones, including an initial positive interim analysis on the Company’s pivotal Phase III TIGeR-PaC clinical trial.
  • The study is evaluating the Company’s lead product candidate, RenovoGem™, and proprietary Trans-Arterial Micro-Perfusion (TAMP™) therapy platform for the treatment of locally advanced pancreatic cancer.

CEO Devin McGranahan Selects Western Union Scholar of the Year

Retrieved on: 
Tuesday, March 12, 2024
Technology, Payments, Finance, Fintech, Professional Services, Philanthropy, University, Foundation, Education, Duquesne University, Patient, Research, Cancer, Student, Biochemistry, Mathematics, Pancreatic cancer, Therapy

The Western Union Company (NYSE: WU) and the Western Union Foundation are proud to recognize Arian Hajihassani as our CEO Scholar of the Year, the organization’s highest scholarship award for the 2023-2024 school year.

Key Points: 
  • The Western Union Company (NYSE: WU) and the Western Union Foundation are proud to recognize Arian Hajihassani as our CEO Scholar of the Year, the organization’s highest scholarship award for the 2023-2024 school year.
  • “Arian’s academic achievements and contributions to medical science as an undergraduate student are truly remarkable,” said Devin McGranahan, CEO of Western Union.
  • “Western Union and the Western Union Foundation are proud to support Arian’s academic journey.
  • Now in his final year, he is thrilled to have been recognized as Devin McGranahan’s Western Union CEO Scholar of the Year, which includes an additional financial award.

Namodenoson Treatment for Pancreatic and Liver Cancer: Data will be Discussed in Out-licensing and Distribution Partnering Meetings at Bio Europe Conference

Retrieved on: 
Monday, March 11, 2024
Oncology, Health, FDA, Diabetes, Clinical Trials, Pharmaceutical, Biotechnology, Conference, CKD, CANF, Business development, Inflammation, Pancreatic cancer, Drug development, Liver cancer, CMS, Pharmaceutical industry

Can-Fite’s pipeline of indications includes Namodenoson for the treatment of advanced liver cancer and pancreatic cancer; both indications have been licensed to the Swiss company Ewopharma for Eastern Europe.

Key Points: 
  • Can-Fite’s pipeline of indications includes Namodenoson for the treatment of advanced liver cancer and pancreatic cancer; both indications have been licensed to the Swiss company Ewopharma for Eastern Europe.
  • The liver cancer indication has been licensed as well to CMS in China and CKD in South Korea.
  • Piclidenoson has been out-licensed to Cipher in Canada; Gebro Pharma for Swiss, Spain, Austria; CMS for China; and Kyongboo for South Korea.
  • “Advanced liver cancer and pancreatic cancer are Can-Fite’s clinical-stage indications for Namodenoson and am delighted with the interest that Namodenoson is raising with companies that will participate in the Bio Europe Conference and are experts in drug development and distribution in the oncology arena.

STARS ALIGN FOR PANCAN PURPLESTRIDE: LISA NIEMI SWAYZE, MISS AMERICA MADISON MARSH AND OTHERS TAKE STEPS TO END PANCREATIC CANCER

Retrieved on: 
Wednesday, April 3, 2024
Diagnosis, Star Trek: Enterprise, ABC, Picard, Disease, Caregiver, Research, Cancer, Pancreatic cancer, Hope, Family, First, Marsh, House, MBA, JD, Survivor, Prairie, Pancreatic Cancer Action Network, Supreme court, Star Trek, Executive producer, LOS

LOS ANGELES, April 3, 2024 /PRNewswire/ -- Today, the Pancreatic Cancer Action Network (PanCAN) announced the participating celebrities who will be lending their voices to this year's PanCAN PurpleStride, the ultimate walk to end pancreatic cancer. PurpleStride will take place nationwide in nearly 60 communities on one big day, April 27, 2024, as survivors, supporters, celebrities and special guests walk in solidarity to raise awareness and much-needed funds for pancreatic cancer, one of the world's deadliest forms of cancer.

Key Points: 
  • The dollars raised directly impact the lives of people facing pancreatic cancer and advance critical progress against the disease.
  • Earlier this year it was announced that the five-year survival rate for pancreatic cancer increased to 13%, steadily growing from 7% over the past decade.
  • Remembering her mother, Whitney, who succumbed to pancreatic cancer in 2018, Marsh will join PurpleStride NYC as a featured speaker.
  • "Pancreatic cancer took my mom from us far too soon, and that's why I'm so proud to be a part of PanCAN PurpleStride.

THE PANCREATIC CANCER ACTION NETWORK NAMES ANNA BERKENBLIT, MD, MMSc AS FIRST-EVER CHIEF SCIENTIFIC AND MEDICAL OFFICER

Retrieved on: 
Tuesday, April 2, 2024
Harvard Medical School, Health, Growth, ImmunoGen, Patient, Research, MD, MBA, Outline of health sciences, Pancreatic Cancer Action Network, Pancreatic cancer, Biomedicine, FDA, MMSc

LOS ANGELES, April 2, 2024 /PRNewswire/ -- The Pancreatic Cancer Action Network (PanCAN), the leading nonprofit in the fight against pancreatic cancer, announces Anna Berkenblit, MD, MMSc, a clinical oncologist and drug developer, as its first-ever chief scientific and medical officer.

Key Points: 
  • LOS ANGELES, April 2, 2024 /PRNewswire/ -- The Pancreatic Cancer Action Network (PanCAN), the leading nonprofit in the fight against pancreatic cancer, announces Anna Berkenblit, MD, MMSc, a clinical oncologist and drug developer, as its first-ever chief scientific and medical officer.
  • "And I'm really excited to join PanCAN to build on our scientific and medical initiatives to take PanCAN to the next phase of growth."
  • "We are honored to welcome Dr. Berkenblit to PanCAN as our first-ever chief scientific and medical officer.
  • She will serve as a thought leader for us in the pancreatic cancer scientific and medical community working with our external advisors and stakeholders," said Fleshman.